| Overview |
| bs-13223R-Cy5.5 |
| FTS/AKTIP Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Rat |
| Human, Mouse, Dog, Cow, Sheep, Pig, Horse, Chicken, Rabbit |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human FTS/AKTIP |
| 201-292/292 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 64400 |
| Cytoplasm, Cell membrane |
| AKT interacting protein; AKT-interacting protein; AKTIP; AKTIP_HUMAN; FT 1; FT1; Fused toes homolog; Fused toes protein homolog. |
| Fused toes protein homolog (FTS), also known as AKT-interacting protein (AKTIP) and Ft1, is a 292 amino acid protein that localizes to the cytoplasm and the cell membrane. A member of the ubiquitin-conjugating enzyme family, FTS binds directly to AKT1 to regulate apoptosis in a cell population. AKT1 is a protein that plays a critical role in a number of cellular responses, such as cell growth, protein synthesis, and antiapoptotic signaling. The interaction of FTS and AKT1 enhances the phosphorylation and activation of AKT1, which, through an AKT1/GSK-3/NFATc1 signaling cascade, results in the increased production of the proapoptotic hormone Fas ligand and thus an increase in apoptosis. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz